Treatments were administered in high glucose DMEM with 1% FBS. High glucose medium was used to improve cell survival, and a low concentration of FBS minimized confounding effects of endogenous growth factors that may be present in the serum. Confluent NTM cells were treated with TGFβ2 (5 ng/mL) (RD Systems, Minneapolis, MN, USA) to induce CLAN formation or DMEM with or without dimethyl sulfoxide (DMSO; vehicle control for MAPK inhibitors). To inhibit the Smad and non-Smad pathways, NTM cells were cotreated with TGFβ2 and TGFβ receptor type I inhibitor SB431542 (5 μM; Sigma, Saint Louis, MO, USA).
27 To inhibit the Smad pathway, NTM cells were cotreated with TGFβ2 and the Smad3 phosphorylation inhibitor SIS3 (10 μM; Sigma).
27 To inhibit the non-Smad pathways, NTM cells were cotreated with TGFβ2 and the JNK inhibitor SP600125 (10 μM; CalBioChem, San Diego, CA, USA),
27 MEK/Erk inhibitor U0126 (25 μM; Promega, Maddison, WI, USA),
44 P38 inhibitor SB203580 (5μM; Tocris BioSci, Ellisville, MO, USA),
27 or ROCK inhibitor Y27632 (10 μM; Sigma).
35,37,44,45 All these inhibitors were used in previous TM studies and have demonstrated successful pathway inhibition at the concentrations described previously. Cells were cotreated with TGFβ2 together with pathway inhibitors for 10 days for studying the prevention of CLAN formation or pretreated with TGFβ2 for 10 days followed by treatment with individual inhibitors for 1 hour to study CLAN resolution. Each treatment group consisted of 6 to 12 coverslips (
n = 6 to 12). Medium was changed every 2 to 3 days.